BT-205
Chronic Pain (Opioid-Experienced Patients)
Key Facts
About Bridge Therapeutics
Bridge Therapeutics is a private, pre-revenue biotech founded in 2019, targeting the dual crises of chronic pain and opioid addiction. The company's strategy centers on two clinical-stage assets: BT-219, designed to improve the delivery of the established OUD treatment buprenorphine-naloxone, and BT-205, a combination therapy intended to allow chronic pain patients to transition off standard opioids without withdrawal or euphoria. Operating as a virtual or lean organization, Bridge is pursuing FDA approval for both programs, aiming to address significant unmet needs in a large and challenging market. The company's mission is to 'separate pain from addiction' by providing therapies that manage pain effectively while minimizing abuse potential.
View full company profile